1. Home
  2. HEPA vs PRSO Comparison

HEPA vs PRSO Comparison

Compare HEPA & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEPA
  • PRSO
  • Stock Information
  • Founded
  • HEPA 2013
  • PRSO 2008
  • Country
  • HEPA United States
  • PRSO United States
  • Employees
  • HEPA N/A
  • PRSO N/A
  • Industry
  • HEPA Biotechnology: Pharmaceutical Preparations
  • PRSO Semiconductors
  • Sector
  • HEPA Health Care
  • PRSO Technology
  • Exchange
  • HEPA Nasdaq
  • PRSO Nasdaq
  • Market Cap
  • HEPA 4.1M
  • PRSO 4.2M
  • IPO Year
  • HEPA N/A
  • PRSO 2001
  • Fundamental
  • Price
  • HEPA $0.57
  • PRSO $1.04
  • Analyst Decision
  • HEPA Hold
  • PRSO Strong Buy
  • Analyst Count
  • HEPA 1
  • PRSO 2
  • Target Price
  • HEPA N/A
  • PRSO $3.38
  • AVG Volume (30 Days)
  • HEPA 27.6K
  • PRSO 125.2K
  • Earning Date
  • HEPA 11-14-2024
  • PRSO 11-12-2024
  • Dividend Yield
  • HEPA N/A
  • PRSO N/A
  • EPS Growth
  • HEPA N/A
  • PRSO N/A
  • EPS
  • HEPA N/A
  • PRSO N/A
  • Revenue
  • HEPA N/A
  • PRSO $12,728,000.00
  • Revenue This Year
  • HEPA N/A
  • PRSO $9.59
  • Revenue Next Year
  • HEPA N/A
  • PRSO $1.63
  • P/E Ratio
  • HEPA N/A
  • PRSO N/A
  • Revenue Growth
  • HEPA N/A
  • PRSO N/A
  • 52 Week Low
  • HEPA $0.48
  • PRSO $0.73
  • 52 Week High
  • HEPA $3.72
  • PRSO $11.20
  • Technical
  • Relative Strength Index (RSI)
  • HEPA 39.66
  • PRSO 55.90
  • Support Level
  • HEPA $0.48
  • PRSO $0.80
  • Resistance Level
  • HEPA $0.66
  • PRSO $1.12
  • Average True Range (ATR)
  • HEPA 0.06
  • PRSO 0.09
  • MACD
  • HEPA -0.01
  • PRSO 0.05
  • Stochastic Oscillator
  • HEPA 32.88
  • PRSO 88.69

About HEPA Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.

Share on Social Networks: